Xilio Therapeutics (NASDAQ:XLO) Posts Earnings Results, Beats Estimates By $0.64 EPS

Xilio Therapeutics (NASDAQ:XLO) issued its quarterly earnings results on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.64, FiscalAI reports. Xilio Therapeutics had a negative return on equity of 71.99% and a negative net margin of 34.06%. The business had revenue of $9.98 million for the quarter, compared to the consensus estimate of $4.92 million.

Here are the key takeaways from Xilio Therapeutics’ conference call:

• Xilio has dosed the first patient in its trial of XTX501, a masked PD-1/IL-2 for post-PD-1 non-small cell lung cancer, and is aiming to report initial efficacy data in Q4 2027. The company says its design may improve tolerability and tumor activity, but clinical differentiation has not yet been demonstrated.
• The company expects to submit INDs for two masked T-cell engagers—PSMA/STEAP1 and CLDN18.2—in Q4 2027. Xilio highlights their dual-targeting, built-in co-stimulation and masking features, but both programs remain preclinical.
• Xilio plans to give Gilead a roughly 40-patient phase II data package for its masked IL-12 in the first half of 2027, after which Gilead will decide whether to exercise its option. The company is also exploring partnership paths for its masked CTLA-4 and T-cell engager programs.
• Current cash runway extends into Q1 2028, covering planned INDs and initial XTX501 data, but extending it further depends on potential collaboration proceeds and a Series C warrant tranche. Xilio said those sources could bring in up to $140 million, but the funding is not assured.

Xilio Therapeutics Trading Down 5.2%

NASDAQ XLO opened at $8.53 on Wednesday. The business’s 50-day moving average price is $8.75 and its 200 day moving average price is $8.50. Xilio Therapeutics has a twelve month low of $6.47 and a twelve month high of $11.30.

Analysts Set New Price Targets

A number of brokerages have commented on XLO. Raymond James Financial assumed coverage on shares of Xilio Therapeutics in a research report on Wednesday, October 21st. They set an “outperform” rating and a $16.00 price objective for the company. Zacks Research raised shares of Xilio Therapeutics to a “hold” rating in a report on Thursday, October 22nd. Finally, Weiss Ratings upgraded shares of Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $16.00.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for cancer. The company’s technology is designed to keep powerful immune-modulating medicines inactive in healthy tissue and activate them preferentially within the tumor microenvironment, with the goal of improving antitumor activity while reducing systemic side effects. Xilio’s research and development programs have included engineered cytokines and immune checkpoint therapies, including tumor-activated versions of interleukin-2, interleukin-12 and CTLA-4-directed treatments.